Association of serum KL-6 levels on COVID-19 severity: A cross-sectional study design with purposive sampling.
AT2
COVID-19
KL-6
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
21
06
2021
revised:
30
07
2021
accepted:
03
08
2021
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
18
8
2021
Statut:
ppublish
Résumé
The main target of SARS-CoV2 is the alveolar type II (AT2) cells of the lung. SARS-CoV2 evades the innate immune system resulting in the release of proinflammatory cytokines (IL-1β, IL-6, TNF-α) which causes AT2 cell damage. Krebs von den Lungen (KL-6) is a specific biomarker of AT2 cell damage. KL-6 is produced in AT2 cells that are injured/regenerated. Research that discusses the role of KL-6 in COVID-19 is still being debated and not much has been done in Indonesia. This study was an analytical study with a prospective design on 75 COVID-19 patients who were treated. Subjects were divided into two large groups according to their degree of severity, 57 subjects with severe degrees and 18 subjects with non-severe degrees. The serum KL-6 levels were measured on days 0 and 6. Data were analyzed using paired In this study, the mean serum KL-6 for day 0 in the severe group was higher than the non-severe group with values of 45.70 U/mL and 44.85 U/mL. On day 6, the mean serum KL-6 in the severe group was lower than that in the non-severe group with values of 41.3 U/mL and 41.95 U/mL. Serum KL-6 in the severe group experienced an even greater decrease than the non-severe group. There was no significant association between serum KL-6 values on 0 days in the severity of COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
The main target of SARS-CoV2 is the alveolar type II (AT2) cells of the lung. SARS-CoV2 evades the innate immune system resulting in the release of proinflammatory cytokines (IL-1β, IL-6, TNF-α) which causes AT2 cell damage. Krebs von den Lungen (KL-6) is a specific biomarker of AT2 cell damage. KL-6 is produced in AT2 cells that are injured/regenerated.
OBJECTIVE
OBJECTIVE
Research that discusses the role of KL-6 in COVID-19 is still being debated and not much has been done in Indonesia.
METHODS
METHODS
This study was an analytical study with a prospective design on 75 COVID-19 patients who were treated. Subjects were divided into two large groups according to their degree of severity, 57 subjects with severe degrees and 18 subjects with non-severe degrees. The serum KL-6 levels were measured on days 0 and 6. Data were analyzed using paired
RESULT
RESULTS
In this study, the mean serum KL-6 for day 0 in the severe group was higher than the non-severe group with values of 45.70 U/mL and 44.85 U/mL. On day 6, the mean serum KL-6 in the severe group was lower than that in the non-severe group with values of 41.3 U/mL and 41.95 U/mL. Serum KL-6 in the severe group experienced an even greater decrease than the non-severe group.
CONCLUSION
CONCLUSIONS
There was no significant association between serum KL-6 values on 0 days in the severity of COVID-19.
Identifiants
pubmed: 34401147
doi: 10.1016/j.amsu.2021.102673
pii: S2049-0801(21)00623-3
pmc: PMC8359564
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102673Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Clin Chim Acta. 2020 Oct;509:280-287
pubmed: 32531256
Aging (Albany NY). 2020 May 29;12(10):9959-9981
pubmed: 32470948
Biosci Trends. 2020 Sep 21;14(4):290-296
pubmed: 32565512
Respir Investig. 2020 Aug 21;:
pubmed: 32863199
J Med Virol. 2020 Oct;92(10):2216-2220
pubmed: 32470148
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 32269085
Respir Res. 2011 Mar 22;12:32
pubmed: 21418654
Clin Immunol. 2020 Dec;221:108614
pubmed: 33153974
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Respir Med. 2012 Dec;106(12):1756-64
pubmed: 22995277
Arterioscler Thromb Vasc Biol. 2020 Nov;40(11):2586-2597
pubmed: 32960072
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1663-1672
pubmed: 32278065
Curr Hypertens Rep. 2020 Aug 27;22(9):63
pubmed: 32852642
Respir Med. 2021 Jul;183:106433
pubmed: 33957434
Semin Respir Crit Care Med. 2013 Aug;34(4):537-48
pubmed: 23934723
Regen Eng Transl Med. 2021 Mar 10;:1-12
pubmed: 33723519
Respir Res. 2020 Nov 24;21(1):309
pubmed: 33234132
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32350106
Clin Rheumatol. 2020 Jul;39(7):2085-2094
pubmed: 32474885
Life Sci. 2020 Aug 1;254:117788
pubmed: 32475810
BMJ. 2020 Oct 23;371:m3862
pubmed: 33097561
Mod Rheumatol. 2019 Jul;29(4):625-632
pubmed: 30484723
J Med Virol. 2021 Apr;93(4):2505-2512
pubmed: 33433006
Int J Surg. 2019 Dec;72:156-165
pubmed: 31704426